<DOC>
	<DOCNO>NCT00163852</DOCNO>
	<brief_summary>Adult cystic fibrosis ( CF ) patient admit acute infection complicate acid-base disturbance decrease ventilation study . They receive salt replacement correct acid-base disturbance possibly ventilation . Assessment symptom ( questionnaire ) , acid-base electrolyte status ( blood urine test ) ventilation ( overnight oxygen carbon dioxide monitor non-invasively ) sleep-wake pattern ( actigraphy ) carry . Study hypothesis : Acute volume electrolyte replacement corrects hypochloremic hypovolemic metabolic alkalosis compensatory hypoventilation/ hypercapnia acute exacerbation cystic fibrosis .</brief_summary>
	<brief_title>Treatment Metabolic Alkalosis Acute Exacerbations Cystic Fibrosis</brief_title>
	<detailed_description>Background : Hypochloremic hypovolemic metabolic alkalosis contributes hypercapnia acute exacerbation cystic fibrosis . Treatment metabolic alkalosis volume sodium chloride ( NaCl ) replacement could reduce hypoventilation hypercapnia , thereby improve symptom , sleep pattern daytime activity level . This would avoid unnecessary treatment non-invasive ventilation . Hypothesis : Volume NaCl replacement corrects hypochloremic hypovolemic metabolic alkalosis compensatory hypoventilation/ hypercapnia acute exacerbation cystic fibrosis result symptomatic improvement . Entry criterion : - Adult cystic fibrosis patient - Admission acute exacerbation - PaCO2 &gt; 45 mmHg - Primary metabolic alkalosis ( acid-base diagram Stinebaugh Austin ) - Serum chloride ( Cl ) ≤ 98 mmol/L - Serum albumin ( alb ) &gt; 25 mmol/L Intervention : - Normal saline intravenously day ( D ) 1,2,3 . ( Replace great Cl deficiency acute weight loss , 2/3 D1 remainder D2 , D3 ) - NaCl tablets 3 tds D4 10 ( calculate replace 7 mmol NaCl loss 60 kg subject ) Random allocation either : 1 . Intervention + standard care ( include standard dietary advice ) D1-10 2 . Standard care alone ( include standard dietary advice ) D1-10 Primary outcome measure : ( D1 , D4 , D10 ) - PaCO2 ( performed time day admission ABG ’ ) - Acid-base status ( Stinebaugh Austin , ABG ’ ) - Serum chloride - Overnight oximetry ( % night SpO2 &lt; 90 % ) PtcCO2 ( rise CO2 overnight ) Secondary outcome measure : ( D1 , D4 , D10 ) - Serum albumin , sodium - Body mass index ( BMI ) - Spirometry ( D1 , D10 ) - Headache scale - Epworth sleepiness scale - Wrist actigraphy ( circadian rhythm daytime activity level ) ( D1-10 ) - Urinary chloride , potassium , sodium , pH , osmolality - Baseline ABG ’ stable outpatient ( within 3 month , pre post admission )</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Alkalosis</mesh_term>
	<criteria>Adult cystic fibrosis patient Admission acute exacerbation ( criteria fall FEV1 &gt; 10 % best last 12/12 , change sputum volume colour , new pulmonary infiltrate ) PaCO2 &gt; 45 mmHg admission Primary metabolic alkalosis ( acidbase diagram Stinebaugh Austin ) Serum chloride ( Cl ) ≤ 98 mmol/L Serum albumin ( alb ) ≤ 25 mmol/L Concurrent diuretic therapy Concurrent glucocorticoid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Metabolic alkalosis</keyword>
	<keyword>Hypercapnia</keyword>
	<keyword>Salt replacement</keyword>
</DOC>